These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 34432123)

  • 21. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
    Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
    Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis.
    Wildman-Tobriner B; Middleton MM; Moylan CA; Rossi S; Flores O; Chang ZA; Abdelmalek MF; Sirlin CB; Bashir MR
    Gastroenterology; 2018 Nov; 155(5):1428-1435.e2. PubMed ID: 30031769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
    Cui J; Philo L; Nguyen P; Hofflich H; Hernandez C; Bettencourt R; Richards L; Salotti J; Bhatt A; Hooker J; Haufe W; Hooker C; Brenner DA; Sirlin CB; Loomba R
    J Hepatol; 2016 Aug; 65(2):369-76. PubMed ID: 27151177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Magnetic Resonance-Based Assessments Better Capture Pathophysiologic Profiles and Progression in Nonalcoholic Fatty Liver Disease.
    Choi SJ; Kim SM; Kim YS; Kwon OS; Shin SK; Kim KK; Lee K; Park IB; Choi CS; Chung DH; Jung J; Paek M; Lee DH
    Diabetes Metab J; 2021 Sep; 45(5):739-752. PubMed ID: 33108854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis.
    Alsaqal S; Hockings P; Ahlström H; Gummesson A; Hedström A; Hulthe J; Johansson L; Niessen HG; Schoelch C; Schultheis C; Vessby J; Wanders A; Rorsman F; Ebeling Barbier C
    J Magn Reson Imaging; 2022 Aug; 56(2):368-379. PubMed ID: 34953171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Magnetic Resonance-Based Elastography and Ultrasound Shear Wave Elastography in Patients With Suspicion of Nonalcoholic Fatty Liver Disease.
    Tahmasebi A; Wessner CE; Guglielmo FF; Wang S; Vu T; Liu JB; Civan J; Lyshchik A; Forsberg F; Li H; Qu E; Eisenbrey JR
    Ultrasound Q; 2023 Jun; 39(2):100-108. PubMed ID: 36943721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating the efficacy of 8 non-invasive models in predicting MASLD and progression: a prospective study.
    Yang A; Zhu X; Zhang L; Zhang D; Jin M; Lv G; Ding Y
    BMC Gastroenterol; 2024 Oct; 24(1):365. PubMed ID: 39402469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective, Same-Day, Direct Comparison of Controlled Attenuation Parameter With the M vs the XL Probe in Patients With Nonalcoholic Fatty Liver Disease, Using Magnetic Resonance Imaging-Proton Density Fat Fraction as the Standard.
    Caussy C; Brissot J; Singh S; Bassirian S; Hernandez C; Bettencourt R; Rizo E; Richards L; Sirlin CB; Loomba R
    Clin Gastroenterol Hepatol; 2020 Jul; 18(8):1842-1850.e6. PubMed ID: 31843596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective Evaluation of Virtual MR Elastography With Diffusion-Weighted Imaging in Subjects With Nonalcoholic Fatty Liver Disease.
    Hanniman E; Costa AF; Bowen CV; Abdolell M; Stueck A; McLeod M; Peltekian K; Rioux J; Clarke SE
    J Magn Reson Imaging; 2022 Nov; 56(5):1448-1456. PubMed ID: 35285996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonalcoholic Fatty Liver Disease, Liver Fibrosis, and Utility of Noninvasive Scores in Patients With Acromegaly.
    Eroğlu İ; Iremli BG; Idilman IS; Yuce D; Lay I; Akata D; Erbas T
    J Clin Endocrinol Metab; 2023 Dec; 109(1):e119-e129. PubMed ID: 37590020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis.
    Middleton MS; Heba ER; Hooker CA; Bashir MR; Fowler KJ; Sandrasegaran K; Brunt EM; Kleiner DE; Doo E; Van Natta ML; Lavine JE; Neuschwander-Tetri BA; Sanyal A; Loomba R; Sirlin CB;
    Gastroenterology; 2017 Sep; 153(3):753-761. PubMed ID: 28624576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis.
    Gu J; Liu S; Du S; Zhang Q; Xiao J; Dong Q; Xin Y
    Eur Radiol; 2019 Jul; 29(7):3564-3573. PubMed ID: 30899974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of Quantitative Imaging Biomarkers for Early-phase Clinical Trials of Steatohepatitis in Adolescents.
    Goyal NP; Sawh MC; Ugalde-Nicalo P; Angeles JE; Proudfoot JA; Newton KP; Middleton MS; Sirlin CB; Schwimmer JB
    J Pediatr Gastroenterol Nutr; 2020 Jan; 70(1):99-105. PubMed ID: 31633654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.
    Loomba R; Kayali Z; Noureddin M; Ruane P; Lawitz EJ; Bennett M; Wang L; Harting E; Tarrant JM; McColgan BJ; Chung C; Ray AS; Subramanian GM; Myers RP; Middleton MS; Lai M; Charlton M; Harrison SA
    Gastroenterology; 2018 Nov; 155(5):1463-1473.e6. PubMed ID: 30059671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver stiffness does not affect ultrasound-guided attenuation coefficient measurement in the evaluation of hepatic steatosis.
    Tada T; Kumada T; Toyoda H; Yasuda S; Sone Y; Hashinokuchi S; Ogawa S; Oguri T; Kamiyama N; Chuma M; Akita T; Tanaka J
    Hepatol Res; 2020 Feb; 50(2):190-198. PubMed ID: 31661724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease.
    Costa-Silva L; Ferolla SM; Lima AS; Vidigal PVT; Ferrari TCA
    Eur J Radiol; 2018 Jan; 98():82-89. PubMed ID: 29279175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy.
    Idilman IS; Aniktar H; Idilman R; Kabacam G; Savas B; Elhan A; Celik A; Bahar K; Karcaaltincaba M
    Radiology; 2013 Jun; 267(3):767-75. PubMed ID: 23382293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis.
    Caussy C; Alquiraish MH; Nguyen P; Hernandez C; Cepin S; Fortney LE; Ajmera V; Bettencourt R; Collier S; Hooker J; Sy E; Rizo E; Richards L; Sirlin CB; Loomba R
    Hepatology; 2018 Apr; 67(4):1348-1359. PubMed ID: 29108123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiparametric magnetic resonance imaging/magnetic resonance elastography assesses progression and regression of steatosis, inflammation, and fibrosis in alcohol-associated liver disease.
    Chen J; Martin-Mateos R; Li J; Yin Z; Chen J; Lu X; Glaser KJ; Mounajjed T; Yashiro H; Siegelman J; Winkelmann CT; Wang J; Ehman RL; Shah VH; Yin M
    Alcohol Clin Exp Res; 2021 Oct; 45(10):2103-2117. PubMed ID: 34486129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.